THE POTENT AND SELECTIVE B3-ADRENOCEPTOR AGONIST MIRABEGRON IMPROVES PATIENT-REPORTED OUTCOMES IN OVERACTIVE BLADDER-RESULTS FROM TWO PHASE III STUDIES

被引：0
|
作者：
Nitti, V [1 ]
Herschorn, S. [2 ]
Auerbach, S. [3 ]
Khullar, V [4 ]
Amarenco, G. [5 ]
Blauwet, M. B. [6 ]
Boerrigter, P. [7 ]
Hakimi, Z. [8 ]
Siddiqui, E. [9 ]
Martin, N. [10 ]
机构：
[1] NYU Langone Med Ctr, Dept Urol, New York, NY USA
[2] Univ Toronto, Div Urol, Toronto, ON, Canada
[3] Hoag Mem Hosp, Newport Beach, CA USA
[4] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Urogynaecol Dept, London, England
[5] Hop Rothschild, Assistance Publ Hop Paris, Dept Neurol Rehabil, Urodynam & Neurophysiol Lab, F-75571 Paris, France
[6] Astellas Pharma Global Dev Inc, Biostat, Deerfield, IL USA
[7] Astellas Pharma Global Dev EU, Leiderdorp, Netherlands
[8] Astellas Pharma Europe, Leiderdorp, Netherlands
[9] Astellas Pharma Europe Ltd, Staines, Middx, England
[10] Astellas Sci & Med Affairs Inc, Deerfield, IL USA
来源：
NEUROUROLOGY AND URODYNAMICS | 2012年 / 31卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
68
引用
收藏
页码：813 / 815
页数：3
相关论文
共 50 条
  • [21] Risankizumab significantly improves patient-reported outcomes in moderate to severe psoriasis in two phase III UltIMMa trials
    Augustin, M.
    Lambert, J.
    Zema, C.
    Thompson, E. H.
    Yang, M.
    Wu, E.
    Geng, Z.
    Valdes, J.
    Skup, M.
    Gordon, K.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 118 - 118
  • [22] CANAKINUMAB IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RECURRENT FEVER SYNDROMES: RESULTS FROM A PHASE 3 TRIAL (CLUSTER)
    Lachmann, Helen J.
    Lauwerys, Bernard
    Miettunen, Paivi
    Kallinich, Tilmann
    Horneff, Gerd
    Brik, Riva
    Manna, Rafaelle
    Murias, Sara
    Savic, Sinisa
    Smeets, Serge
    De Benedetti, Fabrizio
    Simon, Anna
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 207 - 208
  • [23] Bimekizumab Improves Patient-Reported Outcomes in Psoriatic Arthritis: 48-Week Results from a Phase 2b Study and Association Between Patient-Reported Outcomes and Disease Activity
    Gossec, Laure
    Mease, Philip
    Gottlieb, Alice
    Assudani, Deepak
    Coarse, Jason
    Ink, Barbara
    Coates, Laura
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [24] IMPROVED PATIENT-REPORTED OUTCOMES (PROS) WITH MIRABEGRON ADD-ON TREATMENT IN A RANDOMIZED, DOUBLE-BLIND, PHASE 3B STUDY IN INCONTINENT OVERACTIVE BLADDER (OAB) PATIENTS WITH AN INADEQUATE RESPONSE TO SOLIFENACIN
    MacDiarmid, Scott
    Al-Shukri, Salman
    Barkin, Jack
    Fianu-Jonasson, Aino
    Grise, Philippe
    Herschorn, Sender
    Huang, Moses
    Siddiqui, Emad
    Stolzel, Matthias
    Hemsted, Claire
    Drake, Marcus
    JOURNAL OF UROLOGY, 2016, 195 (04): : E849 - E849
  • [25] Safety and tolerability of the β3-adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial
    Nitti, V. W.
    Chapple, C. R.
    Walters, C.
    Blauwet, M. B.
    Herschorn, S.
    Milsom, I.
    Auerbach, S.
    Radziszewski, P.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2014, 68 (08) : 972 - 985
  • [26] Dupilumab Improves Patient-Reported Outcomes In Uncontrolled Persistent Asthma: Results From A Phase 2b Clinical Trial
    Chanez, P.
    Corren, J.
    Castro, M.
    Fabbri, L.
    Joish, V. N.
    Evans, R. E.
    Graham, N. M. H.
    Mastey, V.
    Abbe, A.
    Taniou, C.
    Mahajan, S.
    Teper, A.
    Pirozzi, G.
    Eckert, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [27] Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)
    Herschorn, Sender
    Staskin, David
    Tu, Le Mai
    Fialkov, Jonathan
    Walsh, Terry
    Gooch, Katherine
    Schermer, Carol R.
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2018, 16
  • [28] Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)
    Sender Herschorn
    David Staskin
    Le Mai Tu
    Jonathan Fialkov
    Terry Walsh
    Katherine Gooch
    Carol R. Schermer
    Health and Quality of Life Outcomes, 16
  • [29] Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1)
    Strand, Vibeke
    Mease, Philip
    Gossec, Laure
    Elkayam, Ori
    van den Bosch, Filip
    Zuazo, James
    Pricop, Luminita
    Mpofu, Shephard
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (01) : 203 - 207
  • [30] Effect of Tofacitinib on Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis: Results from 2 Phase 3 Studies
    Strand, Vibeke
    de Vlam, Kurt
    Covarrubias-Cobos, Jose A.
    Mease, Philip J.
    Gladman, Dafna D.
    Hendrikx, Thijs
    Kudlacz, Elizabeth
    Graham, Daniela
    Wu, Joseph
    Cappelleri, Joseph C.
    Hsu, Ming-Ann
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
12345